S&P 500

5.537,02

0,51%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
XOMA Corporation (XOMAP)
XOMA Corporation (XOMAP) Notícias

XOMAP

XOMA (XOMAP)

XOMA Corporation

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:XOMAP

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/06/2024	08:30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAP	XOMA Corporation
18/06/2024	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:XOMAP	XOMA Corporation
13/06/2024	17:31	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:XOMAP	XOMA Corporation
12/06/2024	08:30	GlobeNewswire Inc.	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	NASDAQ:XOMAP	XOMA Corporation
30/05/2024	17:43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XOMAP	XOMA Corporation
17/05/2024	17:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XOMAP	XOMA Corporation
14/05/2024	08:30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	NASDAQ:XOMAP	XOMA Corporation
09/05/2024	08:35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XOMAP	XOMA Corporation
09/05/2024	08:30	GlobeNewswire Inc.	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	NASDAQ:XOMAP	XOMA Corporation
30/04/2024	08:30	GlobeNewswire Inc.	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	NASDAQ:XOMAP	XOMA Corporation
25/04/2024	08:30	GlobeNewswire Inc.	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAP	XOMA Corporation
03/04/2024	10:00	GlobeNewswire Inc.	XOMA Corporation Announces Closing of Tender Offer	NASDAQ:XOMAP	XOMA Corporation
19/03/2024	17:05	GlobeNewswire Inc.	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	NASDAQ:XOMAP	XOMA Corporation
11/03/2024	07:56	Edgar (US Regulatory)	Form S-4 - Registration of securities, business combinations	NASDAQ:XOMAP	XOMA Corporation
08/03/2024	18:34	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:XOMAP	XOMA Corporation
08/03/2024	09:30	GlobeNewswire Inc.	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAP	XOMA Corporation
04/03/2024	19:24	Edgar (US Regulatory)	Form SC TO-T - Tender offer statement by Third Party	NASDAQ:XOMAP	XOMA Corporation
28/02/2024	09:30	GlobeNewswire Inc.	XOMA to Present at Upcoming Investor Conferences in March	NASDAQ:XOMAP	XOMA Corporation
16/02/2024	10:00	GlobeNewswire Inc.	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	NASDAQ:XOMAP	XOMA Corporation
18/01/2024	10:30	GlobeNewswire Inc.	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	NASDAQ:XOMAP	XOMA Corporation
16/01/2024	19:22	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:XOMAP	XOMA Corporation
11/01/2024	18:05	GlobeNewswire Inc.	FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx	NASDAQ:XOMAP	XOMA Corporation
08/01/2024	09:30	GlobeNewswire Inc.	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	NASDAQ:XOMAP	XOMA Corporation
02/01/2024	09:30	GlobeNewswire Inc.	XOMA Announces Stock Repurchase Program of up to $50 Million	NASDAQ:XOMAP	XOMA Corporation
19/12/2023	09:30	GlobeNewswire Inc.	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties	NASDAQ:XOMAP	XOMA Corporation
07/11/2023	09:30	GlobeNewswire Inc.	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAP	XOMA Corporation
31/10/2023	08:30	GlobeNewswire Inc.	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAP	XOMA Corporation
06/09/2023	08:30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:XOMAP	XOMA Corporation
08/08/2023	08:30	GlobeNewswire Inc.	XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy	NASDAQ:XOMAP	XOMA Corporation
23/06/2023	19:14	GlobeNewswire Inc.	XOMA Added to the Russell 2000® and Russell 3000® Indexes	NASDAQ:XOMAP	XOMA Corporation